Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered ...

Fintel reports that on June 20, 2025, William Blair downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...

The death of a second patient taking Sarepta Therapeutics' controversial gene therapy for Duchenne muscular dystrophy caused shares of Sarepta to plunge, and raised questions about the viability of ...